Phase II Prospective Study Evaluating the Role of Pemetrexed Plus Gemcitabine Chemotherapy for Chemo-Naive Select Stage IIIB and IV NSCLC in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy.

Trial Profile

Phase II Prospective Study Evaluating the Role of Pemetrexed Plus Gemcitabine Chemotherapy for Chemo-Naive Select Stage IIIB and IV NSCLC in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 19 May 2010 Planned number of patients changed from 100 to 80 as reported by ClinicalTrials.gov.
    • 17 Feb 2010 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top